Episode
Moderna’s Flu Vaccine Gets FDA Push
- Published
- Jun 18, 2026
- Duration seconds
- 98
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/durham-news-today-2-min-news-the-daily-news-now-7569659/episodes/moderna-s-flu-vaccine-gets-fda-push/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/durham-news-today-2-min-news-the-daily-news-now-7569659/moderna-s-flu-vaccine-gets-fda-push.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Moderna’s mRNA flu vaccine, mFlusiva, is poised to revolutionize flu protection for older adults—FDA approval is imminent for ages 50-64, with broader authorization sought for seniors 65+. Leveraging the same tech that conquered COVID, this vaccine could be deployed faster than traditional shots, crucial as flu strains evolve. Despite earlier FDA pushback over comparison benchmarks, the agency now supports the application, noting promising antibody levels in trials—though gaps remain for the most vulnerable. This marks a major leap in vaccine science, prioritizing those at highest risk. Support the show: Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN: [email protected] This is an automated, high-level news summary based on public reporting. Report issues to [email protected]. View sources & latest updates: https://sources.thednn.ai/88aaf2d9d8bbefff